Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes

Journal of Immunotherapy

Volumn 25, Issue 3, 2002, Pages 207-217

  Tanaka, Hiroshi ^a   Tanaka, Junta ^a   Kjaergaard, Jørgen ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; CD4+CD25+ T cells; Immune regulation; Tumor draining lymph nodes

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; IMMUNOREGULATION; LUNG CANCER; LUNG METASTASIS; LYMPH NODE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR DRAINING LYMPH NODE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; FEMALE; LYMPH NODES; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0036093489     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200205000-00003     Document Type: Article

References (43)

1. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
2. Immune surveillance against a solid tumor fails because of immunologic ignorance
3. + T cells against the wild-type tumor: Correlation with antigen presentation capability
4. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum
5. CD28/B7 system of T cell costimulation
6. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma
7. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
8. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity
9. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
10. Dendritic cells in cancer immunotherapy
11. Regulatory T cells: Key controllers of immunologic self-tolerance
12. + suppressor T cells
13. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases
14. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation
15. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells
16. Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease
17. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance
18. + immunoregulatory T cells is antigen nonspecific
19. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade
20. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin-2 production
21. + regulatory cells that control intestinal inflammation
22. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
23. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody
24. + T cells: A common basis between tumor immunity and autoimmunity
25. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
26. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells
27. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors
28. Treatment of subcutaneous tumor with adoptively transferred T cells
29. Systemic T cell adoptive immunotherapy of malignant gliomas
30. T-cell adoptive immunotherapy of metastatic renal cell carcinoma
31. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: A phase 1 study
32. Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells
33. The selection and characterization of an invasive variant of the B16 melanoma
34. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth
35. Accurate identification of experimental pulmonary metastases
36. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases
37. + T cells with regulatory properties isolated from peripheral blood
38. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function
39. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity
40. + T cells in the priming and effector/memory phases of adoptive immunotherapy
41. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
42. + T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression
43. Immunotherapy of melanoma: A dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy